162 related articles for article (PubMed ID: 9446547)
1. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis.
Takamura T; Kato I; Kimura N; Nakazawa T; Yonekura H; Takasawa S; Okamoto H
J Biol Chem; 1998 Jan; 273(5):2493-6. PubMed ID: 9446547
[TBL] [Abstract][Full Text] [Related]
2. Temporal relationship between immune cell influx and the expression of inducible nitric oxide synthase, interleukin-4 and interferon-gamma in pancreatic islets of NOD mice following adoptive transfer of diabetic spleen cells.
Reddy S; Karanam M; Krissansen G; Nitschke K; Neve J; Poole CA; Ross JM
Histochem J; 2000 Apr; 32(4):195-206. PubMed ID: 10872884
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of a selective inducible nitric oxide synthase (iNOS) inhibitor on pancreatic beta-cell dysfunction.
Kato Y; Miura Y; Yamamoto N; Ozaki N; Oiso Y
Diabetologia; 2003 Sep; 46(9):1228-33. PubMed ID: 12898012
[TBL] [Abstract][Full Text] [Related]
4. The combined inducible nitric oxide synthase inhibitor and free radical scavenger guanidinoethyldisulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1beta-induced suppression of islet insulin secretion in vitro.
Mabley JG; Southan GJ; Salzman AL; Szabó C
Pancreas; 2004 Mar; 28(2):E39-44. PubMed ID: 15028959
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1beta-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo.
Rydgren T; Sandler S
Eur J Endocrinol; 2002 Oct; 147(4):543-51. PubMed ID: 12370118
[TBL] [Abstract][Full Text] [Related]
6. S-methyl-L-thiocitrulline counteracts interleukin 1 beta induced suppression of pancreatic islet function in vitro, but does not protect against multiple low-dose streptozotocin-induced diabetes in vivo.
Sternesjö J; Welsh N; Sandler S
Cytokine; 1997 May; 9(5):352-9. PubMed ID: 9195135
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical study of macrophage influx and the co-localization of inducible nitric oxide synthase in the pancreas of non-obese diabetic (NOD) mice during disease acceleration with cyclophosphamide.
Reddy S; Yip S; Karanam M; Poole CA; Ross JM
Histochem J; 1999 May; 31(5):303-14. PubMed ID: 10461865
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of nitric oxide formation by aminoguanidine: an attempt to prevent insulin-dependent diabetes mellitus.
Holstad M; Jansson L; Sandler S
Gen Pharmacol; 1997 Nov; 29(5):697-700. PubMed ID: 9347312
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1.
Heitmeier MR; Scarim AL; Corbett JA
J Biol Chem; 1997 May; 272(21):13697-704. PubMed ID: 9153221
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic process.
Corbett JA; Mikhael A; Shimizu J; Frederick K; Misko TP; McDaniel ML; Kanagawa O; Unanue ER
Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8992-5. PubMed ID: 7692442
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone can prevent development of type 1 diabetes induced by multiple low-dose streptozotocin in mice.
Ogawa J; Takahashi S; Fujiwara T; Fukushige J; Hosokawa T; Izumi T; Kurakata S; Horikoshi H
Life Sci; 1999; 65(12):1287-96. PubMed ID: 10503944
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic islet blood perfusion in the nonobese diabetic mouse: diabetes-prone female mice exhibit a higher blood flow compared with male mice in the prediabetic phase.
Carlsson PO; Sandler S; Jansson L
Endocrinology; 1998 Aug; 139(8):3534-41. PubMed ID: 9681505
[TBL] [Abstract][Full Text] [Related]
13. Fas and Fas ligand immunolocalization in pancreatic islets of NOD mice during spontaneous and cyclophosphamide-accelerated diabetes.
Redd S; Ginn S; Ross JM
Histochem J; 2002; 34(1-2):1-12. PubMed ID: 12365794
[TBL] [Abstract][Full Text] [Related]
14. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor alpha.
Pakala SV; Chivetta M; Kelly CB; Katz JD
J Exp Med; 1999 Apr; 189(7):1053-62. PubMed ID: 10190896
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in NOD mice.
Suarez-Pinzon WL; Mabley JG; Strynadka K; Power RF; Szabó C; Rabinovitch A
J Autoimmun; 2001 Jun; 16(4):449-55. PubMed ID: 11437493
[TBL] [Abstract][Full Text] [Related]
16. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: identification of iNOS- expressing cells and relationships to cytokines expressed in the islets.
Rabinovitch A; Suarez-Pinzon WL; Sorensen O; Bleackley RC
Endocrinology; 1996 May; 137(5):2093-9. PubMed ID: 8612552
[TBL] [Abstract][Full Text] [Related]
17. Inherent beta-cell dysfunction induced by transgenic expression of allogeneic major histocompatibility complex class I antigen in islet cells.
Mandel TE; Allison J; Campbell IL; Koulmanda M; Malcolm L; Cutri A; Miller JF
Autoimmunity; 1991; 9(1):47-53. PubMed ID: 1669846
[TBL] [Abstract][Full Text] [Related]
18. A critical role for inducible nitric oxide synthase in host survival following coxsackievirus B4 infection.
Flodström M; Horwitz MS; Maday A; Balakrishna D; Rodriguez E; Sarvetnick N
Virology; 2001 Mar; 281(2):205-15. PubMed ID: 11277693
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms underlying resistance of pancreatic islets from ALR/Lt mice to cytokine-induced destruction.
Mathews CE; Suarez-Pinzon WL; Baust JJ; Strynadka K; Leiter EH; Rabinovitch A
J Immunol; 2005 Jul; 175(2):1248-56. PubMed ID: 16002729
[TBL] [Abstract][Full Text] [Related]
20. IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis.
Rothe H; Hausmann A; Casteels K; Okamura H; Kurimoto M; Burkart V; Mathieu C; Kolb H
J Immunol; 1999 Aug; 163(3):1230-6. PubMed ID: 10415018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
